PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology. PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile. PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors." title="" class="btn" data-container="body" data-html="true" data-id="1225" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#0077b5" tabindex="0" data-original-title="PEP-Therapy"> 2,587
Activities
Technologies
Entity types
Location
111 Av. de France, 75013 Paris, France
Paris
France
Employees
Scale: 2-10
Estimated: 15
SIREN
799395215Engaged corporates
7Added in Motherbase
6 years, 4 months agoInnovative peptides as targeted therapies for oncology
PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology.
PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.
PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
cell penetrating peptide, protein-protein interaction, targeted therapies, oncology, clinical trial, and cancer
Innovative peptides as targeted therapies for oncology
PEP-Therapy is a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology.
PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in a number of pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors.
PEP-Therapy was founded in 2014 and builds on research results from Institut Curie and Sorbonne University. The company is backed by international investors.
PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Région Ile de France National and local authorities, Government Administration | Région Ile de France National and local authorities, Government Administration | Other 17 Dec 2024 | | |
![]() Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 17 Dec 2024 | | |
![]() Elsevier Publishing, IT Services and IT Consulting | Elsevier Publishing, IT Services and IT Consulting | Other 30 Sep 2024 | | |
![]() | LUTECH | Other 15 Mar 2024 | | |
![]() Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 4 Sep 2024 | | |
![]() Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Paris Biotech Santé Startup accelerator & VC, Civic and Social Organizations | Other 20 Jul 2023 | | |
![]() Institut Curie Health, Hospitals and Health Care | Institut Curie Health, Hospitals and Health Care | Other 27 Apr 2024 | |